Opinion: Military’s Move into Pharma – Solution or Sovereignty Shortcut?

Tangerang, narasinasi- Indonesia faces a real crisis in healthcare: medicines are notoriously expensive, supply chains fragmented, and rural access remains poor. According to government officials, military-managed labs are set to produce affordable drugs and distribute them directly to village cooperatives at up to 50% below retail price, with the promise of eventual free access to alleviate healthcare burdens. Defense Minister Sjafrie Sjamsoeddin and BPOM head Taruna Ikrar highlight this initiative’s potential to curb pharmaceutical “mafia” operations and fill significant market gaps. Mass production is planned to start in October 2025.

But urgency does not justify institutional overreach. Civil society experts and epidemiologists like Dicky Budiman (Griffith University) warn that involving the military in civilian pharmaceutical production lacks both necessity and legitimacy, and may compromise quality assurance and public trust in health governance. 

The defense sector—traditionally tasked with national sovereignty—should only engage in public healthcare during emergencies or humanitarian crises, not as a permanent solution. Without transparent legal frameworks and clear civilian oversight, this project risks repeating the dangers of Indonesia’s authoritarian past and the notorious dual-function era. 

Moreover, Indonesia already has infrastructures capable of handling drug production: BPOM, Kimia Farma, Indofarma, university laboratories, and a vibrant private pharmaceutical sector all exist yet struggle due to import dependency, regulation inefficiencies, and under-investment in local API fabrication. The real challenge lies in transforming these institutions—not bypassing them with military-led alternatives. 

Instead of expanding TNI’s mandate into healthcare, the government should:

• Strengthen civilian pharmaceutical institutions with capital and R&D incentives,

• Reform policies that govern drug pricing and streamline distribution channels,

• Promote competition that drives innovation, not military monopolies,

• Ensure BPOM and health authorities retain full regulatory control.

In short, public health must not become collateral in a battle for power. While the goal of lowering medicine costs is laudable, sustainable, democratic, and civilian-led reform—not military expansion—is the truest path to pharmaceutical sovereignty.

source: ANTARA News, Tempo, The Jakarta Post.

President Prabowo Taps 82 Young Leaders to Drive Indonesia's Future

Tangerang, narasinasi- President Prabowo Subianto has officially launched the Presidential Fellowship in Economics & Business Leadership, a new national initiative aimed at cultivating a new generation of strategic thinkers to shape Indonesia’s economic future.

Under this program, 82 young professionals—handpicked from top Indonesian and international universities—have been appointed to key national roles. The candidates were rigorously screened by the Ministry of Higher Education, Science, and Technology based on merit, leadership potential, and innovation capabilities.

The fellowship was formalized in late July 2025, and on its launch day, all participants were invited to a five-hour intensive dialogue session with the President at his private residence in Hambalang, Bogor. Discussions centered on Indonesia’s future in science, technology, global business, and economic strategy.

Presidential staffers confirmed that this initiative forms a cornerstone of Prabowo’s long-term leadership development strategy. By empowering youth with high-level exposure and national responsibility, the government aims to ensure continuity and adaptability in responding to global economic shifts.

“This isn’t just a symbolic appointment—it’s an investment in future governance,” said one senior official. The fellows are expected to begin their strategic roles within various ministries and national agencies in the coming months.

Source: ANTARA News — Prabowo’s vision: 82 young leaders driving Indonesia’s growth

Military at the Pharmacy? TNI to Produce Affordable Medicines Nationwide

Tangerang, narasinasi- Indonesia is poised to embark on an unprecedented healthcare initiative as the military, under the coordination of the Ministry of Defense, prepares to manufacture and distribute affordable medicines to the public. Defense Minister Sjafrie Sjamsoeddin signed a memorandum of understanding in late July 2025, authorizing pharmaceutical laboratories run by the Army, Navy, and Air Force to consolidate into a national defense pharmacy unit and begin mass drug production.

Beginning in October, the armed forces will produce essential medications set to be sold at up to 50% below retail price, with plans underway to eventually distribute them for free through the "Red and White Village Cooperatives" across Indonesia.

According to Minister Sjafrie, the initiative aims to reduce the high cost of medicines in Indonesia and improve access for underserved communities. The consolidated pharmaceutical entity—utilizing TNI laboratories—will support nationwide needs beyond military personnel and distribute via village cooperatives, bypassing conventional commercial channels.

Chief of the Navy, Admiral Muhammad Ali, confirmed that the Navy’s pharmaceutical institute (Lafial) will undergo significant expansion. The Pejompongan lab in Jakarta will be upgraded and enlarged to meet production demands. This expansion is part of broader efforts to leverage military infrastructure for the national pharmaceutical sector.

BPOM (Indonesia’s Food and Drug Supervisory Agency) will closely oversee production quality and safety. Head Taruna Ikrar expressed confidence in the discipline and reliability of military-led facilities, emphasizing BPOM’s role in approving drug licenses and ensuring regulatory compliance.

The plan has drawn mixed reactions. Supporters highlight its potential to reduce illegal drug circulation, curb the influence of pharmaceutical “mafia,” and meet public demand for affordable healthcare. Critics—especially human rights groups—warn that this deepens military involvement in civilian domains, recalls authoritarian-era practices, and risks undermining the civilian pharmaceutical industry.

Mass production is scheduled to begin in October 2025. Officials expect the drugs to reach 80,000 cooperatives across rural Indonesia—delivering critical health benefits at significantly reduced prices.

U.S.–Indonesia Trade Accord Opens Doors for U.S. Goods, Lowers Tariffs

Tangerang, narasinasi- In a landmark agreement finalized in late July 2025, the United States and Indonesia have signed a reciprocal trade deal that is set to redefine the commercial relationship between the two nations. The deal significantly reduces tariffs, dismantles non-tariff barriers, and opens the Indonesian market wide to U.S. exports.

Under the terms of the agreement, Indonesia has committed to eliminating trade barriers on more than 99% of U.S. goods—ranging from agricultural products and pharmaceuticals to industrial machinery, ICT, and automobiles. In exchange, the United States will impose a reduced tariff ceiling of 19% on Indonesian exports, down from the 32% threatened under former U.S. President Donald Trump's "Deadlines Day" trade enforcement policy.

“This is a huge win for American businesses and farmers,” Trump declared in a press statement, praising Indonesia’s willingness to make “unprecedented concessions” in order to avoid higher tariffs.

Indonesia, in return, secured a series of high-value commercial commitments. Among them:

• A procurement of $15 billion in U.S. energy products,

• $4.5 billion in U.S. agricultural imports including soybeans and wheat,

• An order of up to 50 Boeing aircraft, marking a major step in the country’s aviation modernization strategy.

The agreement also includes crucial regulatory reforms. Indonesia will now recognize U.S. vehicle safety and emissions standards, FDA approvals for medical products, and will remove pre-shipment inspection requirements. Furthermore, the country has agreed to support cross-border data flow, digital trade liberalization, and remove local content mandates for American firms.

“This deal not only avoids a tariff war but sets a new gold standard for trade agreements in the region,” said a senior official at Indonesia’s Coordinating Ministry for Economic Affairs.

According to economic analysts, the deal benefits both nations strategically. American exporters gain access to Southeast Asia’s largest consumer base, while Indonesia secures critical imports and avoids retaliatory tariffs. The agreement is also seen as a diplomatic pivot for Indonesia amid intensifying U.S.–China trade tensions.

Despite the positive outlook, concerns remain. Indonesian SMEs warn that the influx of American products could hurt local producers. Consumer groups have also raised questions about long-term inflation and the implementation of rules of origin under the deal.

Still, both governments hailed the agreement as a model for future bilateral trade pacts. Negotiations are reportedly ongoing to include zero-tariff access for key Indonesian commodities such as palm oil, coffee, and nickel.

This trade deal positions Indonesia as the most favorably treated ASEAN country under current U.S. trade policy—signaling deeper economic ties between Jakarta and Washington for years to come.

Sources:

• Reuters – Indonesia to Cut Tariffs, Non-Tariff Barriers in US Trade Deal

• White House Press Briefing – Fact Sheet on U.S.–Indonesia Trade Agreement

• IDN Financials – Details of Procurement Commitments

• ASEAN Briefing – Analysis on U.S.–Indonesia Trade Framework

Indonesia Becomes First Exporter of Türkiye’s High-Tech Fighter Jet KAAN

Tangerang, 27 July 2025

Indonesia has become the first international buyer of Türkiye’s latest fifth-generation fighter jet, KAAN, marking a historic milestone in defense cooperation between the two nations. The multi-billion-dollar deal involves the purchase of 48 KAAN units, signaling Indonesia’s ambition to modernize its air force with cutting-edge technology.

The agreement was finalized in late July 2025 after months of negotiations and strategic dialogue. The jets will be delivered gradually over the next few years, with a portion of them assembled jointly in Indonesia to strengthen bilateral technological partnerships. This makes Indonesia not only the first export customer of KAAN but also a key participant in the aircraft’s global rollout.

The KAAN jet, developed by Türkiye’s Turkish Aerospace Industries (TAI), features stealth capabilities, supercruise speed, advanced avionics, and is comparable to the U.S. F-35. The Indonesian Air Force (TNI AU) is expected to use these fighters for both air superiority and precision strike missions.

This move is part of President Prabowo Subianto’s defense modernization agenda, aimed at reducing dependency on traditional Western suppliers and diversifying Indonesia’s military assets. Turkish officials have praised Indonesia’s commitment, stating it sets a precedent for broader defense export markets in Southeast Asia.

Experts say this deal will also impact the balance of air power in the region, given Indonesia’s strategic location and growing role in Indo-Pacific security dialogues. Additionally, joint training programs and industrial cooperation are expected to follow the sale.

source: https://www.hurriyetdailynews.com/turkiye-inks-landmark-deal-to-export-48-kaan-jets-to-indonesia-211885?utm_source=chatgpt.com